Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Greaves, Ronda / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter


IMPACT FACTOR 2018: 3.638

CiteScore 2018: 2.44

SCImago Journal Rank (SJR) 2018: 1.191
Source Normalized Impact per Paper (SNIP) 2018: 1.205

Online
ISSN
1437-4331
See all formats and pricing
More options …
Volume 45, Issue 9

Issues

Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention

Andries J. Bakker
  • 1Stichting Klinisch Chemisch Laboratorium, Medical Centre Leeuwarden, Leeuwarden, Netherlands
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Matthias Mücke
Published Online: 2007-09-11 | DOI: https://doi.org/10.1515/CCLM.2007.254

Abstract

Monoclonal gammopathy is characterized by the presence of an M-protein in serum or urine that has homogeneous structural and functional properties. It can occur in very high concentrations and may cause significant interference in clinical chemistry assays. Examples of gammopathy interference for the analytes glucose, bilirubin, γ-glutamyltransferase, urea and ferritin are presented. Various mechanisms of interference are described, such as the production of turbidity by the M-protein and the binding of the M-protein to a component of the test system or analyte. In immunoglobulin tests, the M-protein is the analyte itself and may not be completely bound by the test antibody owing to its structural properties. Modern analyzers can detect unusual changes in absorption during the course of a reaction, and thus the formation of turbidity due to M-proteins. This interference may be prevented by optimizing the buffering conditions of the reagents to avoid the formation of turbidity or by removal of the M-protein prior to analysis of the sample. Owing to the unique properties of each M-protein, it is impossible to protect common clinical chemistry test systems completely from gammopathy interference. Therefore, efficient ways for the detection of such interference are needed.

Clin Chem Lab Med 2007;45:1240–3.

Keywords: gammopathy; interference; paraprotein; M-protein

About the article

Corresponding author: Dr. Matthias Mücke, Roche Diagnostics GmbH, LR-HA, Nonnenwald 2, 82377 Penzberg, Germany Phone: +49-8856-605559, Fax: +49-8856-605594,


Received: 2007-03-06

Accepted: 2007-05-04

Published Online: 2007-09-11

Published in Print: 2007-09-01


Citation Information: Clinical Chemical Laboratory Medicine, Volume 45, Issue 9, Pages 1240–1243, ISSN (Online) 14374331, ISSN (Print) 14346621, DOI: https://doi.org/10.1515/CCLM.2007.254.

Export Citation

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Roy Beryl Julinta, Thangapalam Jawahar Abraham, Anwesha Roy, Jasmine Singha, Satyanarayana Boda, and Prasanna Kumar Patil
Ecotoxicology and Environmental Safety, 2019, Volume 186, Page 109752
[2]
Sandip Kumar Kundu, Indira Bhaskar Biswas, Nirmalya Roy, and Nibedita Basu
Journal of Evolution of Medical and Dental Sciences, 2017, Volume 6, Number 29, Page 2353
[3]
Rick H. A. van der Doelen, Paul Nijhuis, Robert van der Velde, and Marcel J. W. Janssen
Clinical Case Reports, 2018
[5]
EL Cuttance, WA Mason, RA Laven, J McDermott, and CVC Phyn
New Zealand Veterinary Journal, 2017, Page 1
[6]
EL Cuttance, WA Mason, KS Denholm, and RA Laven
New Zealand Veterinary Journal, 2017, Volume 65, Number 1, Page 6
[7]
Michael O. Alberti, Thomas A. Drake, and Lu Song
Practical Laboratory Medicine, 2015, Volume 3, Page 8
[8]
Lu Song, Kathleen A. Kelly, and Anthony W. Butch
Archives of Pathology & Laboratory Medicine, 2014, Volume 138, Number 7, Page 950
[9]
Donald F. LeGatt, George B. Blakney, Trefor N. Higgins, Kareena L. Schnabl, Carol E. Shalapay, Valerian C. Dias, and James C. Wesenberg
Therapeutic Drug Monitoring, 2012, Volume 34, Number 3, Page 306
[10]
Prasanth Krish and Kenar D. Jhaveri
Kidney International, 2012, Volume 81, Number 6, Page 603
[11]
Albert Wolthuis
Bioanalysis, 2011, Volume 3, Number 19, Page 2223
[12]
Philip Goldwasser, Nagarathna G. Manjappa, Carol A. Luhrs, and Robert H. Barth
American Journal of Kidney Diseases, 2011, Volume 58, Number 4, Page 617
[13]
Christof Schild, Florence Egger, Alain Kaelin-Lang, and Jean-Marc Nuoffer
Clinical Chemistry and Laboratory Medicine, 2011, Volume 49, Number 7
[14]
Olivier Decaux, Elisabeth Laurat, Antoinette Perlat, Claire Cazalets, Patrick Jego, and Bernard Grosbois
European Journal of Internal Medicine, 2009, Volume 20, Number 5, Page 457
[15]
Richard I. King and Christopher M. Florkowski
Pathology, 2010, Volume 42, Number 5, Page 397
[16]
Wytze Oosterhuis, Henne Kleinveld, and Matthias Mücke
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 5
[17]
Milos Tichy, Bedrich Friedecky, Marek Budina, Vladimir Maisnar, Tomas Buchler, Magdalena Holeckova, Dagmar Gotzmannova, and Vladimir Palicka
Clinical Chemistry and Laboratory Medicine, 2009, Volume 47, Number 2
[18]
Pieter Vermeersch and Zahur Zaman
Clinical Chemistry and Laboratory Medicine, 2008, Volume 46, Number 9
[19]
Jessica Zuin, Gianluca Veggiani, Paolo Pengo, Andrea Gallotta, Alessandra Biasiolo, Natascia Tono, Angelo Gatta, Patrizia Pontisso, Radovan Toth, Dean Cerin, Vladimir Frecer, Sabrina Meo, Massimo Gion, Giorgio Fassina, and Luca Beneduce
Clinical Chemistry and Laboratory Medicine, 2010, Volume 48, Number 2
[20]
Gottfried Rudofsky, Matthias Villalobos, Ruediger Waldherr, Matthias Schaier, Markus Zorn, Anna Maimer, Martin Zeier, Peter P. Nawroth, and Berend Isermann
Kidney International, 2010, Volume 77, Number 4, Page 371

Comments (0)

Please log in or register to comment.
Log in